Ozempic-Class Drugs Face Real-World Test: $13.3m Trial on Addiction, Jobs and Justice

The weight-loss drugs that reshaped medicine's approach to obesity are about to face their most ambitious real-world test yet — not for waistlines, but for addiction, employment, housing and encounters with the criminal justice system.

A new $13.3 million randomised controlled trial, announced this week, will test whether weekly injections of semaglutide — the GLP-1 drug sold as Ozempic and Wegovy — can reduce alcohol and opioid use and improve life outcomes for up to 1,200 adults in Allegheny County, Pennsylvania. The study is a collaboration between the Center for Addiction Science, Policy and Research (CASPR), a nonprofit focused on GLP-1 drugs as addiction treatments, and the Allegheny County Department of Human Services.

As reported by STAT News, the trial is expected to launch in early 2027. Half of the participants will be randomly assigned to receive semaglutide weekly for 52 weeks as an addition to standard addiction care — not as a replacement for it — while researchers track their progress through the county's linked administrative data.

A trial that looks beyond the clinic

Most addiction-medication trials measure one thing: whether people use less of the substance in question. This study is deliberately designed to look further. Alongside alcohol and opioid use, researchers will measure criminal-justice involvement, employment, housing stability and health-care utilisation — the factors that determine whether someone in recovery can actually rebuild a life.

Recruitment will focus on people at elevated risk of criminal-justice involvement who are clinically appropriate for GLP-1 medications.

Who is behind the study

The trial is being run by CASPR, a nonprofit organisation dedicated to researching GLP-1 drugs as treatments for addiction, in partnership with the Allegheny County Department of Human Services. It is funded through a $13.3 million grant from Arnold Ventures, a US philanthropy that finances research on social problems, to CASPR.

The lead clinical site will be the University of Pittsburgh Medical Center (UPMC) Western Psychiatric Hospital's Addiction Medicine Services. The study is multi-site and is expected to enrol up to 1,200 adults with alcohol use disorder, opioid use disorder, or both.

The evidence so far: promising, but early

A wave of clinical trials has begun testing whether GLP-1 weight-loss drugs can quiet various substance-use disorders, with some promising early results.

• Observational data: A June 2026 study led by researchers at the University of Texas at El Paso, published in Frontiers in Psychiatry, examined more than 142,000 cases of patients with type 2 diabetes or obesity, of whom around 20,000 were prescribed GLP-1 medications. It found that GLP-1 users had 74 per cent lower odds of alcohol use disorder, 69 per cent lower odds of opioid use disorder, 68 per cent lower odds of nicotine use disorder and 75 per cent lower odds of cocaine use disorder than similar counterparts not on the drugs. The authors stressed the study was observational and does not establish cause and effect.
• Oral semaglutide for drinking: An eight-week randomised, double-blind, placebo-controlled trial at CU Anschutz in 50 adults with moderate-to-severe alcohol use disorder found that oral semaglutide led to fewer heavy drinking days, reduced consumption per drinking occasion, lower day-to-day cravings and fewer alcohol-related problems.
• Veterans' trial: The US Department of Veterans Affairs has launched a trial of semaglutide for alcohol use disorder in more than 600 veterans across 18 VA medical centres, tracking changes in drinking, health and quality of life over 24 weeks.
• NIDA-funded research: Multiple US National Institute on Drug Abuse-funded Phase II trials are assessing semaglutide's effects on alcohol and opioid use disorders, with results anticipated in late 2026 to 2027.

The biological hypothesis is that GLP-1 drugs influence dopamine signalling and other neural pathways involved in reward and craving — not only for food, but for alcohol and other substances.

How the researchers interpret the findings

Nicholas Reville, executive director and co-founder of CASPR, said the trial was "designed to be easy for other cities to adopt, if there is a positive outcome", adding: "Because this is a medication, rather than a complex program, if it works in Pittsburgh, it should work almost everywhere."

Alex Jutca, director of the Allegheny County Department of Human Services, said the study was an opportunity to build on promising early indications about the potential of GLP-1 receptor agonists "while including those who might benefit most from these medications". Jutca added: "If this trial can show that we have a way to give people a better chance to recover, stay healthy, find employment, maintain stable housing, and prevent reinvolvement in the justice system, we will have made a major advance."

Limitations and caveats

The enthusiasm comes with important qualifications. First, the strongest population-level findings so far are observational: the UTEP study's authors explicitly said they do not support prescribing GLP-1 drugs for addiction treatment at this time, and that randomised trials are needed before any such recommendation.

Second, the smaller randomised trials completed so far are short and involve dozens of participants, not thousands. Whether effects on cravings and drinking persist over a year — and translate into the harder outcomes this new trial measures, like employment and desistance from crime — is precisely what remains unknown.

Third, the trial population is specific: adults with alcohol or opioid use disorder in one US county, at elevated risk of criminal-justice involvement. Results may not generalise to other populations, health systems or substances. And GLP-1 drugs carry their own side-effect profile and cost questions, which will matter if policymakers are asked to fund them at scale.

What it adds to the GLP-1 evidence base

If successful, the trial would move the conversation about GLP-1 drugs beyond metabolism and into social policy. Demonstrating that a weekly injection can shift not just substance use but employment, housing stability and reoffending would give governments a fiscal as well as a clinical argument for funding treatment — the trial is explicitly designed to capture total fiscal and social costs for that reason. Results, if the early-2027 launch holds, would likely emerge in 2028 or later.

FAQs

Is this a new study or a new trial?

It is a new trial, announced this week via EurekAlert and covered by STAT News. The $13.3 million randomised controlled trial is a collaboration between the nonprofit Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services in Pennsylvania, funded by a grant from Arnold Ventures. It is expected to launch in early 2027 and enrol up to 1,200 adults — making it one of the largest studies of its kind.

What will participants actually do?

Half of the participants will be randomly assigned to receive once-weekly semaglutide injections for 52 weeks, on top of their existing addiction treatment — the drug is an additional support, not a replacement, and everyone remains eligible for other behavioural health services. The other half will receive standard care. Researchers will then compare the two groups across substance use, criminal-justice involvement, employment, housing and health-care use.

Why focus on criminal justice and employment rather than just substance use?

Because those are the outcomes that determine whether recovery sticks. Addiction researchers and policymakers increasingly recognise that reduced substance use alone does not capture whether someone can hold a job, keep housing or avoid reoffending. The trial will use Allegheny County's linked administrative data to track these real-world outcomes — a design choice that could, if the results are positive, give governments a financial case for funding GLP-1-based addiction treatment.

Could Ozempic become an addiction treatment?

Not yet, and researchers are explicit about that. The biological rationale is plausible — GLP-1 drugs appear to influence dopamine signalling and reward pathways involved in craving — and early observational and small-trial data are encouraging. But the UTEP researchers behind the largest observational study said they do not support prescribing these drugs for addiction at this time. Randomised evidence, including from this trial and NIDA-funded Phase II studies reporting in late 2026 to 2027, will be needed before regulators or clinicians act.

What are the main caveats?

Three stand out. First, the headline population data are observational and cannot prove cause and effect. Second, completed randomised trials are small and short, so durability and real-world impact are unproven. Third, the new trial's population — adults with alcohol or opioid use disorder at elevated risk of justice-system involvement in one US county — is specific, so results may not generalise. Side effects and the high cost of GLP-1 drugs would also need to be weighed against any benefits.